Functional antibodies as immunological endpoints to evaluate protective immunity against Shigella
JournalHuman vaccines & immunotherapeutics
PublisherTaylor & Francis
MetadataShow full item record
AbstractThe development, clinical advancement and licensure of vaccines, and monitoring of vaccine effectiveness could be expedited and simplified by the ability to measure immunological endpoints that can predict a favorable clinical outcome. Antigen-specific and functional antibodies have been described in the context of naturally acquired immunity and vaccination against Shigella, and their presence in serum has been associated with reduced risk of disease in human subjects. The relevance of these antibodies as correlates of protective immunity, their mechanistic contribution to protection (e.g. target antigens, interference with pathogenesis, and participation in microbial clearance), and factors that influence their magnitude and makeup (e.g. host age, health condition, and environment) are important considerations that need to be explored. In addition to facilitating vaccine evaluation, immunological correlates of protection could be useful for identifying groups at risk and advancing immune therapies. Herein we discuss the precedent and value of functional antibodies as immunological endpoints to predict vaccine efficacy and the relevance of functional antibody activity to evaluate protective immunity against shigellosis.
SponsorsThis work was supported by NIH awards R01AI117734 and R01AI125841 and a Research Supplement to Promote Diversity in HealthRelated Research Program, 3R01AI117734-04S1.
Keywordcorrelates of protection
threshold of protection
trials for developing countries
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85079019823&doi=10.1080%2f21645515.2019.1640427&partnerID=40&md5=a18a351cff778715e8542322ca035fff; http://hdl.handle.net/10713/12016
- Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study.
- Authors: Shimanovich AA, Buskirk AD, Heine SJ, Blackwelder WC, Wahid R, Kotloff KL, Pasetti MF
- Issue date: 2017 Feb
- Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis.
- Authors: Cohen D, Meron-Sudai S, Bialik A, Asato V, Goren S, Ariel-Cohen O, Reizis A, Hochberg A, Ashkenazi S
- Issue date: 2019
- Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
- Authors: Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer AM, Kaminski RW, Porter CK, Chakraborty S, Clarkson KA, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts H, Feijoo BL, Halpern J, Sack D, Riddle MS, Fonck VG
- Issue date: 2021 Apr
- Repertoire of Naturally Acquired Maternal Antibodies Transferred to Infants for Protection Against Shigellosis.
- Authors: Ndungo E, Andronescu LR, Buchwald AG, Lemme-Dumit JM, Mawindo P, Kapoor N, Fairman J, Laufer MK, Pasetti MF
- Issue date: 2021
- Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.
- Authors: Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB
- Issue date: 2007 Jul